BRIELLYN Drug Patent Profile
✉ Email this page to a colleague
When do Briellyn patents expire, and when can generic versions of Briellyn launch?
Briellyn is a drug marketed by Glenmark Generics and is included in one NDA.
The generic ingredient in BRIELLYN is ethinyl estradiol; norethindrone. There are twenty-six drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone profile page.
Summary for BRIELLYN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Formulation / Manufacturing: | see details |
DailyMed Link: | BRIELLYN at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for BRIELLYN
US Patents and Regulatory Information for BRIELLYN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glenmark Generics | BRIELLYN | ethinyl estradiol; norethindrone | TABLET;ORAL-28 | 090538-001 | Mar 22, 2011 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |